MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025)
MapLight Therapeutics' (MPLT) quarterly Free Cash Flow came in at -$47.2 million in Q4 2025, down 118.6% year-on-year from $253.8 million in Q4 2024, and down 118.6% quarter-over-quarter from -$21.6 million in Q4 2024.
MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025) Analysis & Trends
MapLight Therapeutics has disclosed Free Cash Flow across 2 years of filings, most recently posting -$47.2 million for Q4 2025.
- Free Cash Flow for Q4 2025 came in at -$47.2 million, down 118.6% year-over-year; the trailing twelve-month figure through Dec 2025 was -$68.8 million (changed N/A YoY), and the FY2025 annual result was -$138.6 million, down 74.17% from the prior year.
- Free Cash Flow came in at -$47.2 million for Q4 2025 at MapLight Therapeutics, down from -$21.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$21.6 million in Q4 2024 to a low of -$47.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | MapLight Therapeutics | 248.88 Mn | 248.88 Mn | - | -47.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -47.21 Mn |
| Dec 31, 2025 | -47.21 Mn |
| Dec 31, 2024 | -21.59 Mn |
| Dec 31, 2024 | -21.59 Mn |